Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.
Commentary|Videos|May 16, 2025
Decoding T-Cell Lymphomas: An Approach to Diagnosis & Treatment
Author(s)Kerry Savage, MD, MSc, Neha Mehta-Shah, MD
Kerry Savage, MD, MSc, and Neha Mehta-Shah, MD, discuss approaches to diagnosing and treating T-cell lymphomas.
Advertisement
Kerry Savage, MD, MSc, and Neha Mehta-Shah, MD, discuss approaches to diagnosing and treating T-cell lymphomas.
Advertisement
Related to this article
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
The FDA has approved pimicotinib for patients with symptomatic tenosynovial giant cell tumors.
Frailty is common among older adults with blood cancers and strongly predicts survival, independent of age.
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pimicotinib for Symptomatic TGCT
2
Dr Backes on BEHOLD-1 Data With Mocertatug Rezetecan in Platinum-Resistant Ovarian Cancer
3
Dr Patel on How Zidesamtinib Data From ARROS-1 Compare With Taletrectinib Data From TRUST-I/TRUST-II in ROS1-Positive NSCLC
4
Longer Follow-Up of BEHOLD-1 Shows Durable Responses With Mo-Rez in Platinum-Resistant Ovarian Cancer
5